Biotest GmbH KGaA (LTS:0N6Z) ROIC %: 0.00% (As of . 20)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

What is Biotest GmbH KGaA ROIC %?

Biotest GmbH KGaA LTS:0N6Z ROIC % is 0.00% as of . 20.

ROIC % measures how well a company generates cash flow relative to the capital it has invested in its business. It is also called ROC %. Biotest GmbH KGaA's annualized return on invested capital (ROIC %) for the quarter that ended in . 20 was 0.00%.

As of today (2026-08-12), Biotest GmbH KGaA's WACC % is 0.00%. Biotest GmbH KGaA's ROIC % is 0.00% (calculated using TTM income statement data). Biotest GmbH KGaA earns returns that do not match up to its cost of capital. It will destroy value as it grows.


Biotest GmbH KGaA  (LTS:0N6Z) ROIC % Explanation

ROIC % measures how well a company generates cash flow relative to the capital it has invested in its business. It is also called ROC %. The reason book values of debt and equity are used is because the book values are the capital the company received when issuing the debt or receiving the equity investments.

There are four key components to this definition. The first is the use of operating income or EBIT rather than net income in the numerator. The second is the tax adjustment to this operating income or EBIT, computed as a hypothetical tax based on an effective or marginal tax rate. The third is the use of book values for invested capital, rather than market values. The final is the timing difference; the capital invested is from the end of the prior year whereas the operating income or EBIT is the current year's number.

Why is ROIC % important?

Because it costs money to raise capital. A firm that generates higher returns on investment than it costs the company to raise the capital needed for that investment is earning excess returns. A firm that expects to continue generating positive excess returns on new investments in the future will see its value increase as growth increases, whereas a firm that earns returns that do not match up to its cost of capital will destroy value as it grows.

As of today, Biotest GmbH KGaA's WACC % is 0.00%. Biotest GmbH KGaA's ROIC % is 0.00% (calculated using TTM income statement data). Biotest GmbH KGaA earns returns that do not match up to its cost of capital. It will destroy value as it grows.


Be Aware

Like ROE % and ROA %, ROIC % is calculated with only 12 months of data. Fluctuations in the company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective.


Biotest GmbH KGaA ROIC % Related Terms


Biotest GmbH KGaA ROIC % Historical Data

* Premium members only.

The historical data trend for Biotest GmbH KGaA's ROIC % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Biotest GmbH KGaA ROIC % Chart

Biotest GmbH KGaA Annual Data
Trend
ROIC %

Biotest GmbH KGaA Semi-Annual Data
ROIC %

LTS:0N6Z vs : ROIC % Comparison

For the Biotechnology subindustry, Biotest GmbH KGaA's ROIC %, along with its competitors' market caps and ROIC % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Biotest GmbH KGaA ROIC % vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Biotest GmbH KGaA's ROIC % distribution charts can be found below:

* The bar in red indicates where Biotest GmbH KGaA's ROIC % falls into.



Biotest GmbH KGaA ROIC % Calculation

Biotest GmbH KGaA's annualized Return on Invested Capital (ROIC %) for the fiscal year that ended in . 20 is calculated as:

ROIC % (A: . 20 )
=NOPAT/Average Invested Capital
=Operating Income * ( 1 - Tax Rate % )/( (Invested Capital (A: . 20 ) + Invested Capital (A: . 20 ))/ count )
= * ( 1 - % )/( ( + )/ )
=/
= %

where

Biotest GmbH KGaA's annualized Return on Invested Capital (ROIC %) for the quarter that ended in . 20 is calculated as:

ROIC % (Q: . 20 )
=NOPAT/Average Invested Capital
=Operating Income * ( 1 - Tax Rate % )/( (Invested Capital (Q: . 20 ) + Invested Capital (Q: . 20 ))/ count )
= * ( 1 - % )/( ( + )/ )
=/
= %

where

Note: The Operating Income data used here is one times the annual (. 20) data. The tax rate is limited to between 0% and 100%.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about ROIC % →
What does a ROIC % of 0.00% mean?
Biotest GmbH KGaA (LTS:0N6Z) has a ROIC % of 0.00% as of . 20. Return on invested capital is the ratio of current-period net income to average two-period invested capital. View historical data on Biotest GmbH KGaA and its competitors.
Is Biotest GmbH KGaA's ROIC % too high?
Biotest GmbH KGaA's current ROIC % is 0.00%.
How does Biotest GmbH KGaA's ROIC % compare to ?
Biotest GmbH KGaA's ROIC % of 0.00% can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROIC % for a Biotechnology company?
A good ROIC % depends on the Biotechnology industry context. However, ROIC % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROIC % mean?
A high ROIC % can signal that a stock is expensive relative to its fundamentals. Return on invested capital is the ratio of current-period net income to average two-period invested capital. View historical data on Biotest GmbH KGaA and its competitors. Biotest GmbH KGaA's current ROIC % is 0.00%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Biotest GmbH KGaA stock overvalued right now?
Biotest GmbH KGaA (LTS:0N6Z) has a current ROIC % of 0.00%. The current ROIC % is 0.00%. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROIC % calculated?
ROIC % is calculated from a company's financial statements. For Biotest GmbH KGaA (LTS:0N6Z), the current ROIC % is 0.00% as of . 20. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Biotest GmbH KGaA Business Description

Comparable Companies
Biotest GmbH & Co KGaA is a specialist in haematology, clinical immunology, and intensive care medicine. The group develops, manufactures, and markets plasma proteins and biotherapeutic drugs. The group's value chain extends from pre-clinical and clinical development to world-wide marketing and distribution. It manufactures immunoglobulins, clotting factors, and albumins, which are derived from human blood plasma. The group markets its products in Europe, the Middle East, China, Australia, Africa, and the USA.